The global DTaP vaccine market is anticipated to grow at a significant CAGR of 6.5% during the forecast period 2022-2028. Vaccination seeks to boost the immune system's ability to combat specific antigens. The DTaP vaccine is used to protect newborns from diphtheria, tetanus, and pertussis by injecting antigens that are weaker versions of the target viruses. When the body is exposed to comparable antigens in the future, these antigens develop antibodies. As a result, market growth is expected to be fuelled by an increase in preventative care among consumers. Most vaccines, including the DTaP, are administered to children when their immune systems are still growing. This element is expected to propel the market forward.

Furthermore, the advent of combination vaccines suggested for vaccination programmes to lower the number of injections necessary while maintaining immunisation compliance in newborns is expected to boost the DTaP vaccine market. The DTaP vaccine protects against three diseases: diphtheria, tetanus, and pertussis. As a result, the decrease of those doses as part of a combination vaccine is projected to provide enormous market growth prospects in the coming years. Infants should receive three doses of DTaP, according to the Centre for Disease Control and Prevention (CDC), to build up high levels of protection against tetanus, whooping cough, and diphtheria.

Impact of Covid-19 on Global DTaP Vaccine Market

The sudden emergence of the COVID-19 prompted the installation of strict lockdown measures in some countries, causing a substantial influence on the DTaP vaccine market. Due to the lockdown, the vaccination of these DTaP vaccines was stopped. As a result, the global DTaP vaccine market saw a declining phase. There was an increased threat of these vaccination preventable diseases to spread among children. Although, as soon as the restrictions were lifted, the vaccination started again immediately. The gap in vaccines that was caused due to lockdown could not be covered up even after increasing per day vaccination count. 

Segmental Outlook

The global DTaP vaccine market is segmented based on disease type and end-user. Based on the disease type, the market is sub-segmented into diphtheria, tetanus, and pertussis. Based on end-user, the market is sub-segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Diphtheria and tetanus are expected to contribute less in the market growth as the complete DTaP vaccine have 100% clinical efficacy in Diphtheria and 97% clinical efficacy in tetanus. 

Global DTaP Vaccine Market Share by Disease Type, 2021 (%)

The Pertussis Segment is Anticipated to Hold a Prominent Share in the Global DTaP Vaccine Market

The pertussis segment is anticipated to hold the largest share in the market due to increased awareness among people of harmful bacteria. Regarding pertussis, there has been an overall increasing trend in reported cases since the 1980s. Despite this, pertussis affects many fewer people today than before due to the availability of pertussis-containing vaccines. The factors which propel the growth of this segment are improved diagnostic tests, better reporting, more circulation of bacteria, and waning immunity. Due to increased awareness among people, more clinical visits are being done for the diagnostic of the infection. The demand for DTaP vaccines is therefore being increased, contributing to the growth of the market.

Regional Outlooks

The global DTaP vaccine market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East & Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement. During the projection period, North America is expected to see significant market expansion. The acellular pertussis vaccines used in the United States do not protect for as long as the prior whole-cell pertussis vaccine. A sharp increase in cases of tetanus and diphtheria can be seen in this region. 

Global DTaP Vaccine Market Growth, by Region 2022-2028

The North America Region is Estimated to Hold the Major Share in the Global DTaP Vaccine Market

The North American region is expected to hold a significant share in the global DTaP vaccine market due to the increasing cases of tetanus and diphtheria Pharmaceutical companies have started developing new vaccines for the prevention of such harmful diseases among infants. For instance, in February 2021, Merck & Co. Inc. and Sanofi SA, jointly developed VAXELIS, the first and only hexavalent (six-in-one) combination vaccine available in the U.S. indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type B. VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age. 

Market Players Outlook

GlaxoSmithKline PLC, Sanofi SA, Pfizer Inc., and Bharat Biotech Ltd., among others, are some of the leading participants in the global DTaP vaccine market industry. To increase market share around the world, these companies are using a variety of techniques, including mergers and acquisitions, product launches, geographic expansion and collaboration, and partnership. For instance, in August 2021, as a part of Sanofi’s endeavour to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company entered into a definitive agreement with Translate Bio, under which Sanofi SA will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion. The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global DTaP vaccine market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market